Xeploitrazole 100 Capsule contains Itraconazole 200 mg, a broad-spectrum triazole antifungal agent indicated for the treatment of various systemic and superficial fungal infections. Itraconazole exerts its antifungal activity by inhibiting the cytochrome P450-dependent enzyme lanosterol 14-α-demethylase, which is essential for the conversion of lanosterol to ergosterol, a key component of fungal cell membranes. This disruption impairs membrane synthesis, leading to increased cellular permeability and ultimately fungal cell death. Xeploitrazole 100 Capsule is prescribed for infections caused by dermatophytes, yeasts, and molds, including onychomycosis, blastomycosis, histoplasmosis, aspergillosis, and candidiasis. The medication is administered orally, with absorption enhanced when taken with food. Dosage and duration depend on the type and severity of the infection, and therapy should be guided by clinical response and mycological assessment. Caution is advised in patients with hepatic impairment or congestive heart failure, as itraconazole may cause hepatotoxicity and negative inotropic effects. Drug interactions are significant due to itraconazole’s inhibition of CYP3A4; therefore, concomitant use with certain medications requires careful monitoring or avoidance. Patients should adhere strictly to prescribed regimens and consult healthcare providers if adverse effects or signs of hypersensitivity occur.